Condition: AML · AML With Mutated NPM1 · Hematologic Malignancy · Sponsor: Kura Oncology, Inc.
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
This description comes directly from the study's public registry record.
Kura Medical Information · 844-KURAONC (844-587-2662) · medinfo@kuraoncology.com
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | Recruiting |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| UCLA Health - Bowyer Oncology Center | Los Angeles, California, United States | Recruiting |
| UC Irvine Health Chao Family Comprehensive Cancer Center | Orange, California, United States | Recruiting |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Smilow Cancer Hospital at Yale New Haven | New Haven, Connecticut, United States | Recruiting |
| Emory Healthcare - The Emory Clinic | Atlanta, Georgia, United States | Recruiting |
| Georgia Cancer Center at Augusta University | Augusta, Georgia, United States | Recruiting |
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago, Illinois, United States | Recruiting |
| Loyola University Medical Center | Maywood, Illinois, United States | Recruiting |
| Simmons Cancer Institute | Springfield, Illinois, United States | Withdrawn |
+ 33 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06001788